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Abstract
Background: Bcl-2 (B cell lymphoma/leukemia gene-2) is the first proto-oncogene recognized to function by inhibiting
programmed cell death/apoptosis. Although much is known about the anti-apoptotic ability of Bcl-2, little information
is available concerning its function in other cellular processes, such as cell differentiation.
Methods: In this study, stable cell lines from pre-malignant MCF10ATG3B mammary epithelial cells, a cell line derived
from a human proliferative breast disease model, to express exogenous Bcl-2 was established. CMV promoter driven
Bcl-2 expression vector or empty vector was transfected into MCF10ATG3B human mammary epithelial cells to
investigate the effects of Bcl-2 on mammary epithelial cells. In addition, western blot and immunofluoresence
staining were employed to testify the marker proteins of both mesenchymal and epithelial cells.
Results: Unexpectedly, a dramatic change of phenotype from epithelial cells to fibroblast-like cells was observed
in Bcl-2-transfected cells. Western blot analysis and immunofluoresence staining results demonstrated that the
E-cadherin and desmoplakin, markers of epithelial cells, were downregulated in the Bcl-2-transfected cells. However,
N-cadherin and vimentin, markers of mesenchymal cells, were upregulated in these cells. Redistributions of cytokeratin
and beta-catenin were also observed in the Bcl-2-transfected cells. Our results further showed that the Bcl-2-transfected
MCF10ATG3B cells retained some epithelial markers, such as epithelial specific antigen (ESA) and epithelial membrane
antigen (EMA), indicating their epithelial origin. In addition, cell migration and invasion was substantially increased in
Bcl-2 transfected cells.
Conclusion: Taken together, our results strongly indicate that in addition to its anti-apoptotic function, Bcl-2 is also
involved in the epithelial-mesenchymal transition (EMT), a fundamental mechanism in normal morphogenesis and
pathogenesis of some diseases.
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Background
Proto-oncogene Bcl-2 (B cell lymphoma/leukemia gene-2)
is a main member of Bcl-2 family, which plays a central
role in regulation of programmed cell death pathways by
suppressing (e.g. Bcl-2, Bcl-XL) or promoting (e.g. Bax,
Bak, Bad, Bcl-Xs) apoptosis. It has been demonstrated that
Bcl-2 expression is required for long-term cell survival or
cell transformation [1–3]. Bcl-2 inhibits apoptosis induced
by a variety of stimuli including tumor necrosis factor
(TNF), cytotoxic drugs, and ionizing radiation [1–3].
Although much is known about the anti-apoptotic
ability of Bcl-2, little information is available concern-
ing its functions in other cellular processes, such as
cell differentiation.
Proliferation, differentiation, and apoptosis are pro-
cesses tightly regulated during development and tissue
homeostasis, allowing amplification along specific line-
ages while preventing excess proliferation of immature
cells. Dysregulation of these processes contributes to
some diseases including cancer. Epithelial cell adhesion
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and communication with the extracellular matrix (ECM)
and neighboring cell play fundamental roles in epithelial
trans-differentiation into a mesenchymal phenotype which
involves in some stress kinases, phosphatase2A, and phos-
phositide 3-kinase (PI3-kinase)/protein kinase B (AKT)
[4–7], which share some similar signal transduction path-
ways with apoptosis regulation pathways of Bcl-2 family.
In this study, we showed that the constitutive expression
of Bcl-2 in human mammary epithelial MCF10ATG3B
cells induced epithelial-mesenchymal transition (EMT).
Our results thus indicate that in addition to its anti-
apoptotic function, Bcl-2 may be also involved in EMT
during normal morphogenesis and tumorigenesis.
Methods
Antibodies
Antibodies against E-cadherin, N-cadherin, α-catenin, β-
catenin and γ-catenin were purchased from BD Science
Transduction Laboratories (Lexington, KY, USA). Anti-
bodies against Desmoplakin I&II, vimentin (AB-2), Epi-
thelial Specific Antigen (Ab-2) and Epithelial Membrane
Antigen (Ab-2) were obtained from LabVision Corpor-
ation (Fremont, CA, USA). The β-actin antibody, the
goat anti-mouse IgG-HRP, the goat anti-rabbit IgG-HRP
and the donkey anti-goat IgG-HRP antibodies were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Anti-rabbit and mouse Alexa Fluor 488 antibodies
were purchased from Invitrogen Life Technologies (Grand
Island, NY, USA).
Cell culture and DNA transfection
MCF10AT3B epithelial cells were obtained from Karma-
nos Cancer Institute (Detroit, MI, USA) [8]. MCF10AT3B
cells and its derivatives were maintained at 37 °C in a 5 %
CO2 atmosphere in DMEM/F12 supplemented with 5 %
horse serum, L-Glutamine (2 mM), penicillin (100 U/ml),
streptomycin (100 μg/ml), hydrocordisone (0.5 μg/ml),
insulin (10 μg/ml), Epidermal growth factor (EGF) (2 ng/
ml), and clolera toxin (0.1 μg/ml). For DNA transfection,
cells were plated at a density of 1 × 105 per 60-mm dish
and transfected 24 h later with a pcDNAI-Bcl-2 expres-
sion vector driven by the cytomagalovirus (CMV) pro-
moter (kindly provided by Dr. HR-C Kim at Wayne State
University) as described before [9]. using FuGene6 trans-
fection reagent (Promega, Madison, WI, USA) according
to the manufacture’s instruction. DNA transfection was
performed with 15 μg of linearized expression vector and
5 mg of an expression vector containing G418 resistant
marker gene. The empty expression vector was used as a
control. Forty-eight hours after transfection, the cells were
re-plated and selected with 500 μg/ml of G418 (Invitrogen
Life Technologies). The medium was changed every three
days until colonies appeared. Individual single colonies
were then isolated and expanded to confirm expression of
Bcl-2 by Western blot analysis.
Western blot analysis
Cells were washed with cold phosphate buffer saline (PBS)
and lysed with the radio-immunoprecipitation assay (RIPA)
buffer containing 1 % proteinase inhibitor cocktail solution
and 1 % phosphatase inhibitor cocktail solution (Sigma, St.
Louis, MO, USA). The cell lysates were boiled for 5 min in
sodium dodecyl sulfate (SDS) gel-loading buffer and
separated on 10 % SDS-PAGE gels. After electrophoresis,
the proteins were transferred to a polyvinylidene fluoride
(PVDF) membrane (Bio-Rad Laboratories, Hercules, CA).
The membranes were probed with appropriate primary
antibodies and visualized with the corresponding sec-
ondary antibodies and the electro-chemi-luminescence
(ECL) kit (Thermo Scientific, Rockford, IL, USA). The
same membranes were stripped and re-probed with an
antibody for β-actin to confirm equal loadings.
Indirect immunofluorescence staining
Cells were fixed in 4 % paraformaldehyde for 10 min,
then permeabilized in 0.1 % Triton X-100 for 5 min,
blocked in 1 % BSA for 30 min, and then incubated with
primary antibodies at 4 °C overnight. Secondary anti-
bodies, anti-rabbit or mouse Alexa Fluor 488 was then
added and incubated for 1 h at room temperature. Cells
were washed with PBS and mounted with 10 mg/ml
DAPI (4, 6-diamidino-2-phenylindole dihydrochloride)
(Sigma-Aldrich, St. Louis, MO, USA) in aqueous mount-
ant (Dako, Carpinteria, CA, USA) and photographed
using a fluorescent Nikon microscope at a 63× magnifi-
cation. Images were captured using the MRC-1024 con-
focal Imaging System (Bio-Red, Hercules, CA, USA).
Cell viability assay
To determine cell viability, 5 × 104 of cells were seeded
in triplicate onto 35-mm dishes, treated with different
concentrations of serum, hydrocordisone withdrawal, and
different concentrations of TNF (R & D systems, Minne-
apolis, MN, USA) for five days, then trypsinized and the
cell viability was determined with the ADAM automatic
cell counter (Digital Bio. Hopkinton, MA, USA) according
to the manufacture’s recommendation.
Migration and invasion assay
The cells were plated at a density of 1 × 106 per 60-mm
dish, incubated for 24 h, and drew a line with a sterilized
pipette tip on the dish bottom to take off the cells, then
changed to fresh medium. After incubation for another
24 h, cell migration was examined and photographed.
To measure invasion ability of these cells, we used a
24-well BD BioCoat Matrigel Invasion Chamber (BD
Biosciences, Bedford, MA, USA). An equal number of
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cells (2.5 × 104/ml) in 0.5 ml medium were loaded into
the top chamber of each well. After incubating the
chamber for 24 h, non-migrating cells were scraped
from upper surface of the filter. The cells on lower sur-
face were fixed with ethanol, stained with Diff-Quick
Stain Set (Andwin Scientific Direct, Schaumburg, IL,
USA), and photographed.
Statistical analysis
Data were summarized as the mean ± standard error (SE)
using the GraphPad InStat software program (GraphPad
Software, La Jolla, CA, USA). Tukey-Kramer Multiple
Comparisons Test was used, and the significance was
accepted for p < 0.05.
Results
Constitutively expression of Bcl-2 in MCF10ATG3B cells
attenuates apoptosis induced by serum starvation,
hydrocordisone withdrawal and TNF-a treatment
To investigate the effects of Bcl-2 on mammary epithe-
lial cells, we transfected MCF10ATG3B human mam-
mary epithelial cells either with a CMV promoter driven
Bcl-2 expression vector or with an empty vector, and se-
lected transfectants with G418 for three weeks. The cell
colonies were isolated and expanded. The expression of
Bcl-2 in the clonal cell lines was then evaluated with
Western blot analysis. Our results showed that Bcl-2
was highly expressed in the Bcl-2-transfected cells com-
pared with control cells transfected with the empty vector
(Fig. 1a). We also observed endogenous Bcl-2 expression
in the control cells (Fig. 1a).
We established a number of stable cell lines that
expressed Bcl-2, two of which are described in detail in
this report (Bcl-2-1, −3). We also generated two control
cell lines transfected with the empty vector (CMV-5, −6).
The growth rate of each cell line was determined by
counting the number of cells daily. There was no signifi-
cant difference in the growth rate between the Bcl-2-
expressing cells and control cells (data not shown). We
then decided to determine whether the transfected Bcl-2
was functionally active in the transfectants by examining
the effect of Bcl-2 on programmed cell death/apoptosis.
First, we cultured cells in medium containing different
concentrations of serum and found the viability of control
cells was dramatically reduced in lower concentrations of
serum; about 60 % cells were non-viable in the medium
containing 1.25 % serum while Bcl-2 expressing cells were
more resistant to serum starvation (Fig. 1b). It has been
Fig. 1 Effects of constitutive Bcl-2 expression on the morphology of MCF10ATG3B cells. a Western blot analysis of the cell lysates from Bcl-2-transfected
cells (Bcl-2-1 and −3) and control cells transfected with empty expression vector (CMV-5 and −6) using an anti-Bcl-2 specific antibody and an anti-actin
antibody to ensure an equal loading. b BCl-2-1 and CMV-5 cells were cultured in different concentrations of serum as indicated for three days, or cultured
in medium with or without hydrocordisone for two days, or treated with different concentrations of TNF for two days. Cell survival assays were performed
as described in Methods
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reported previously that hydrocordisone is vital to nor-
mal growth of MCF10A cells in culture and hydrocordi-
sone withdrawal will induce cell apoptosis in MCF10A
cells [10, 11]. We cultured cells in the absence of hydro-
cordisone and found that Bcl-2 expression attenuated
cell apoptosis induced by hydrocordisone withdrawal
(Fig. 1b). Tumor necrosis factor (TNF) is a potent in-
ducer of cell apoptosis [6]. We found that Bcl-2 express-
ing cells were also resistant to TNF-induced apoptosis
compared to control cells (Fig. 1b). Our data thus indi-
cated that the constitutive expression of exogenous Bcl-
2 inhibited apoptosis induced by serum starvation, TNF
treatment and hydrocordisone withdrawal and suggesting
that transfected Bcl-2 is functionally active in the trans-
fected cells.
Constitutively expression of Bcl-2 in MCF10ATG3B cells
induces epithelial to mesenchymal transition
Unexpectedly, we also observed a dramatic change of
phenotype from epithelial cells to fibroblast-like cells in
the Bcl-2-transfected MCF10ATG3B cells that exhibited
a highly elongated and spindle-shaped phenotype and
failed to form extensive cell-cell contacts. However, the
vector transfected MCF10ATG3B cells still kept epithelial
characteristic (Fig. 2).
Since the Bcl-2-expressing MCF10ATG3B cells ac-
quired a fibroblast-like morphology, we next examined
the marker proteins of both mesenchymal and epithelial
cells by Western blot analysis (Fig. 3) and immuno-
fluoresence staining (Fig. 4).
Transmembrane cadherins are a family of cell-cell
adhesion molecules that play a central role in tissue
morphogenesis and homeostasis. Cadherin function is
regulated by its association with the actin containing
cytoskeleton, an association mediated by a complex of
cytoplasmic proteins, the catenins: α, β and γ. We first
noted that the expression profile of junctional proteins was
markedly altered in the Bcl-2-expressing MCF10ATG3B
cells compared with the control cells (Fig. 4). Western blot
analysis demonstrated that the expression of the epithelial
specific proteins, E-cadherin and epithelial membrane
antigen (EMA) were almost completely downregulated in
the Bcl-2-expressing cells. However, N-cadherin, a main
mesenchymal marker, was highly expressed in these
cells. We also observed protein bands recognized by
pan-cadherin antibody were different in two Bcl-2 ex-
pressing cell lines, suggesting that relative levels of these
proteins may be different in two cell lines. In accordance
with Western blot results, confocal immunofluorescence
microscopy revealed a membrane and also a cytoplasmic
distribution of N-cadherin in the Bcl-2-expressing cells.
E-cadherin and epithelial specific antigen (ESA) were
still detectable above background levels in the Bcl-2-
expressing cells, but disappeared from the plasma mem-
brane and scattered in the cytoplasm. In contrast, a very
strong immuno-staining of these proteins was observed
on the plasma membrane in the control cells. Concomi-
tantly, the localization of the catenins was also markedly
altered. β-catenin was co-localized with E-cadherin along
the entire plasma membrane in the control cells, but
Fig. 2 Constitutive Bcl-2 expression induces morphology change. Cell morphologies were examined in Bcl-2 transfected cells and control cells at
different cell density under a microscope and photographed (magnification X 40)
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mainly found in the cytoplasm and appeared to be inde-
pendent of E-cadherin in the Bcl-2-expressing cells. In
addition, desmoplakin was detected as dot-like struc-
tures in the cytoplasm; disappeared from the plasma
membrane of the BCl-2-expressing cells, indicating that
desmosomal structures were internalized as large com-
plexes upon loss of epithelial polarity. We also observed
a dramatic change in the expression of vimentin,
another mesenchymal marker. Western blot analysis
showed that vimentin was detected as closely spaced
double-band of ~44kD and ~40kD in the Bcl-2-expressing
cells, but only a very weak band at ~44kD in the vector
control cells. Immunofluorescence staining showed a
cytoplasmic threadlike structure of vimentin in the Bcl-2-
expressing cells compared a weaker staining in the control
cells (Fig. 4).
Fig. 3 Constitutive Bcl-2 expression induces an epithelial-mesenchymal transition associated with the loss of epithelial markers and the gain of
mesenchymal markers. Western blot analysis of expression levels of epithelial and mesenchymal markers in Bcl-2 transfected cells and control cells
using antibodies specific to E- and N-cadherin, α, β, and γ-catenin, vimentin, and epithelial membrane antigen (EMA)
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Bcl-2-overexpressing MCF10ATG3B cells display a higher
migratory and invasion capability than control cells
The acquisition of an EMT phenotype prompted us to
examine the migration and invasion ability of Bcl-2- ex-
pressing cells. A typical in vitro wound-healing assay was
performed. We found that Bcl-2 expressing cells showed
more rapid closure of the wound created in a two-
dimensional culture compared to control cells (p < 0.01;
Fig. 5a and b). We next tested the invasive ability of the
Bcl-2 expressing cells through matrigel-coated filters and
found only the Bcl-2-expressing cells invaded through
matrigel, and exhibited a dramatically increased number of
invading cells compared to the control cells (p < 0.01; Fig. 5c
and d). Our results indicated a directly or indirectly involve-
ment of Bcl-2 in the acquisition of EMT-like phenotype
that paralleled the enhanced motility and invasive ability.
Discussion
Programmed cell death or apoptosis is a highly regu-
lated process responsible for the removal of damaged
and unnecessary cells. The dynamic interplay between
pro-death proteins (BAX, BAK, BAD, BIM, NOXA, and
PUMA) and pro-survival proteins (BCL-2, BCL-XL, and
BCL-W) controls cell apoptosis [2]. Dysregulation of
the balance between these opposing proteins may result
in uncontrolled cell growth and even tumorigenesis.
The tumorigenic potential of the overexpression of the
anti-apoptotic gene Bcl-2 was first described as a result
of the chromosomal translocation seen in subsets of
non-Hodgkin’s lymphoma, where it has been found to
be tumorigenic [1–3]. Enhanced expression of Bcl-2 has
been identified in other malignancies, including breast
cancer, where its pathological function is less clear [10, 11].
In this study, we revealed an additional function of Bcl-2;
its constitutive expression has a profound morphological ef-
fect on mammary epithelial cells, MCF10AT3B. First, Bcl-2
transfected cells displayed elongated and spindle-shaped
morphologies, a typical fibroblastoid phenotype. Second,
these morphologic changes are associated with the loss of
epithelial markers such as E-cadherin and the gain of
mesenchymal markers such as N-cadherin and vimentin.
Third, the adherens junctions among cells are completely
diminished and all catenins and E-cadherin are downregu-
lated and redistributed. Fourth, the Bcl-2 expressing cells
Fig. 4 Immunofluorescent evidence of epithelial-mesenchymal trasition induced by constiutive Bcl-2 expression associated with the loss of epithelial
markers and the gain of mesenchymal markers. Cells were fixed and immunofluorescent staining was performed using antibodies specific
to E- and N-cadherin, β-catenin, desmoplakin I&II, vimentin and epithelial specific antigen (ESA) and FITC-conjugated secondary antibodies.
The images were photographed under a Bio-Rad MRC1024 confocal scanning laser microscope (magnification X 60)
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acquired enhanced motile and invasive activities. All of
these changes resemble a typical EMT process, which is
characterized by the loss of epithelial properties and the
gain of mesenchymal features [4–7].
Analysis of cellular marker protein expression indi-
cated that the effect of constitutive Bcl-2 expression on
cells is not limited to cell morphology. Constitutive Bcl-
2 expression affects expression of genes that determine
cellular behaviors such as the loss of epithelial cellular
marker E-cadherin and the gain of mesenchymal N-
cadherin. The shift in expression from E- to N-cadherin
in Bcl-2 transfected cells again indicated that Bcl-2 ex-
pression induced a typical EMT. Previously, it was re-
ported that forced expression of N-cadherin in breast
cancer cells MCF-7 induces cell migration, invasion and
metastasis without changes of the endogenous expression
or adhesive function of E-cadherin and cell epithelial phe-
notypes [12], suggesting cell migration and invasion is a
cellular process independent of the EMT. Thus, it is
likely that the induced N-cadherin expression in Bcl-2-
transfected cells is responsible for the enhanced cell mo-
tile and invasive activities observed, whereas E-cadherin
downregulation contributes to the disassembly of the
adherens junctions during Bcl-2 trigged EMT.
The importance of E-cadherin in maintaining epithelial
phenotype is well documented [13]. The downregulation
of E-cadherin expression and function is a critical step
during EMT and in the malignant progression of most
epithelial tumors [4]. Here, we observed that E-cadherin is
downregulated and redistributed in Bcl-2 transfected cells.
Currently, it is unclear how constitutive Bcl-2 expression
results in loss of E-cadherin expression. The transcription
repressors such as Snail [14], SIP1 (ZEB-2) [15] and Twist
[16] suppress the transcription of E-cadherin gene and in-
duce EMT. Recently, it was reported that Bcl-2 physically
interacts with Twist1, which leads to transcriptional regu-
lation of Twist target gene such as E-cadherin [17]. Thus,
Bcl-2 may be directly involved in transcriptional regula-
tion of the transcription factors involved in regulation of
E-cadherin expression.
Conclusions
Our results here are in good agreement with the previous
reports of Bcl-2 function in invasion and metastasis
[18–21] and that Bcl-2 over expression influences E-
cadherin expression and promote EMT in different types of
cells [17, 22, 23]. Moreover, gene expression profiles in hu-
man cancers indicated that de-differentiated cancer cells
share EMT properties with a stem-like phenotype [24]. A
direct link between EMTand cancer stem cells was demon-
strated by findings that EMTactivators, such as Twist1, can
induce both EMTand stemness [25, 26]. Thus, it will be in-
teresting to investigate the function of Bcl-2 induced EMT
in the stemness of human breast cancer stem-like cells.
Fig. 5 Constitutive Bcl-2 expression induces a migratory and invasive
phenotype. a The motility behavior of control cells and Bcl-2 transfected
cells was analyzed in an in vitro wound-healing assay. b Statistical
significance (p < 0.01) exhibited for the Bcl-2 transfected cells with
stronger migratory capability (N = 3; mean = 65.33; SE = 3.51) than the
control ones (N = 3; mean = 11; SE = 2.0).. Data showed the counted
cell numbers, and represented as mean ± s.e.m. c The invasive features
of the control and Bcl-2 expressing cells were analyzed in an invasion
assay on matrigel in a BioCoat Matrigel Invasion Chamber. The cells
adhered to the lower surface of the filters were fixed and stained
with a Diff-Quik Stain Set, photographed under a light microscope.
d Statistical significance (p < 0.01) exhibited for the Bcl-2 transfected
cells with stronger invasive potential (N = 3; mean = 57.67; SE = 4.51)
than the control ones (N = 3; mean = 4.67; SE = 1.53)
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